Skip to main content
PMC home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 2000 Jan;91(1):99–104. doi: 10.1111/j.1349-7006.2000.tb00865.x

In vitro Antitumor Activity, Intracellular Accumulation, and DNA Adduct Formation of cis‐[((1R, 2R)‐1,2‐Cyclohexanediamine‐N, N')bis(myristato)] Platinum (II) Suspended in Lipiodol

Shuichi Kishimoto 1,✉, Kenji Miyazawa 1, Shoji Fukushima 1, Yoshikazu Takeuchi 1
PMCID: PMC5926231  PMID: 10744050

Abstract

SM‐11355, cis‐[((1R,2R)‐1,2‐cyclohexanediamine‐N,N')bis(myristato)] platinum (II), is a lipophilic platinum complex under clinical development that targets primary hepatocellular carcinoma using Lipiodol as a carrier. SM‐11355 was compared with cisplatin (CDDP) using an in vitro evaluation system capable of examining the release characteristics and the cytotoxicity of drugs suspended in Lipiodol. SM‐11355 suspended in Lipiodol (SM‐11355/Lipiodol) and CDDP suspended in Lipiodol (CDDP/Lipiodol) showed cytotoxic activity against rat ascites hepatoma AH‐109A cells in a dosedependent manner. Their IC50 values following 7‐day exposure were 22.3 and 0.40 μg/ml, respectively. Following the subsequent 7‐day exposure, from day 7 to day 14 after preparation of the suspension, SM‐11355/Lipiodol showed an almost equivalent activity, but CDDP/Lipiodol did not show any activity at all. SM‐11355/Lipiodol showed a sustained release into the culture medium over the course of a 14‐day exposure. Following the exposure to CDDP/Lipiodol, the platinum concentration in the medium was at its maximum on the first day and remained constant thereafter. Intracellular platinum uptake and formation of platinum‐DNA adducts were dependent on the release characteristics of each drug suspension. For SM‐11355/Lipiodol, the drug release, intracellular drug uptake, and formation of platinum‐DNA adducts over the course of the subsequent 7‐day exposure were similar to those observed during the first 7 days. DPC, one of the compounds released from SM‐11355/Lipiodol, was taken up by cells and showed formation of platinum‐DNA adducts. Thus, this study suggests that SM‐11355/Lipiodol may release active platinum compound(s) that bind to nuclear DNA and mediate the cytotoxic activity of SM‐11355/Lipiodol.

Keywords: Lipiodol, Cisplatin, Hepatocellular carcinoma, Sustained release

Full Text

The Full Text of this article is available as a PDF (73.8 KB).

REFERENCES

  • 1. ) Minoyama , A. , Yoshikawa , M. , Ebara , M. , Saisho , H. , Sugiura , N. and Ohto , M.Study of repeated arterial infusion chemotherapy with a subcutaneously implanted reservoir for advanced hepatocellular carcinoma . J. Gastroenterol. , 30 , 356 – 366 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 2. ) Rougier , P. , Munck , J. N. , Elias , D. , Herait , P. , Bongel , C. , Gosse , C. and Lasser , P.Intra‐arterial hepatic chemotherapy with pirarubicin. Preclinical and clinical studies . Am. J. Clin. Oncol. , 13 , S1 – S4 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 3. ) Vexler , A. M. , Mou , X. , Gabizon , A. A. and Gorodetsky , R.Reduction of the systemic toxicity of cisplatin by intra‐arterial hepatic route administration for liver malignancies . Int. J. Cancer , 60 , 611 – 615 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 4. ) Iwai , K. , Maeda , H. and Konno , T.Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X‐ray image . Cancer Res. , 44 , 2115 – 2121 ( 1984. ). [PubMed] [Google Scholar]
  • 5. ) Konno , T.Targeting cancer chemotherapeutic agents by use of lipiodol contrast medium . Cancer , 66 , 1897 – 1903 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 6. ) Yamashita , Y. , Takahashi , M. , Bussaka , H. , Fukushima , S. , Kawaguchi , T. and Nakano , M.Intraarterial infusion of 5‐fluoro‐2‐deoxyuridine‐C8 dissolved in a lymphographic agent in malignant liver tumors. A preliminary report . Cancer , 64 , 2437 – 2444 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 7. ) Shibata , J. , Fujiyama , S. , Sato , T. , Kishimoto , S. , Fukushima , S. and Nakano , M.Hepatic arterial injection chemotherapy with cisplatin suspended in an oily lymphographic agent for hepatocellular carcinoma . Cancer , 64 , 1586 – 1594 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 8. ) Bayraktar , Y. , Balkanci , F. , Kayhan , B. , Uzunalimoglu , B. , Gokoz , A. , Ozihik , Y. , Gurakar , A. , van Theil , D. H. and Filat , D.A comparison of chemoembolization with conventional chemotherapy and symptomatic treatment in cirrhotic patients with hepatocellular carcinoma . Hepatogastroenterology , 43 , 681 – 687 ( 1996. ). [PubMed] [Google Scholar]
  • 9. ) Hirashima , N. , Sakakibara , K. , Itazu , I. , Hirai , T. , Nemoto , A. , Matsuura , H. , Kumada , K. , Nojiri , O. and Kano , H.Zinostatin stimalamer‐transcatheter arterial embolization for hepatocellular carcinoma: a comparison with Lipiodoltranscatheter arterial embolization . Semin. Oncol. , 24 , S6 – 91 – S6 – 96 ( 1997. ). [PubMed] [Google Scholar]
  • 10. ) Konno , T. , Maeda , H. , Iwai , K. , Tashiro , S. , Maki , S. , Morinaga , T. , Mochinaga , M. , Hiraoka , T. and Yokoyama , I.Effect of arterial administration of high‐molecularweight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report . Eur. J. Cancer Clin. Oncol. , 19 , 1053 – 1065 ( 1983. ). [DOI] [PubMed] [Google Scholar]
  • 11. ) Konno , T. , Kai , Y. , Yamashita , R. , Nagamitsu , A. and Kimura , M.Targeted chemotherapy for unresectable primary and metastatic liver cancer . Acta Oncol. , 33 , 133 – 137 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 12. ) Seymour , L. W. , Olliff , S. P. , Poole , C. J. , De Takats , P. G. , Orme , R. , Ferry , D. R. , Maeda , H. , Konno , T. and Kerr , D. J.A novel dosage approach for evaluation of SMANCS [poly‐(styrene‐co‐maleyl‐half‐n‐butylate)‐neocarzinostatin] in the treatment of primary hepatocellular carcinoma . Int. J. Oncol. , 12 , 1217 – 1223 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 13. ) Fukushima , S. , Kishimoto , S. , Hayashi , Y. , Kaneko , M. and Nakano , M.Intra‐hepatic artery infusional chemotherapy with cisplatin suspension in lipiodol (LPS) of hepatocellular carcinoma (I)—preparation of LPS and its anticancer effect on a rabbit liver cancer model after injection into the hepatic artery . J. Jpn. Soc. Cancer Ther. , 23 , 2743 – 2749 ( 1988. ). [PubMed] [Google Scholar]
  • 14. ) Maeda , M. , Uchida , N. A. and Sasaki , T.Liposoluble platinum (II) complexes with antitumor activity . Jpn. J. Cancer Res. ( Gann ), 77 , 523 – 525 ( 1986. ). [PubMed] [Google Scholar]
  • 15. ) Kishimoto , S. , Fukui , M. , Fukushima , S. and Nakano , M.Application of a lipophilic platinum derivative contained in an oily lymphographic agent to intra‐hepatic arterial chemotherapy . Reg. Cancer Treat. , 1 – 2 , 25 – 29 ( 1992. ). [Google Scholar]
  • 16. ) Han , I. , Khokhar , A. R. and Perez‐Solar , R.Intraliposomal conversion of lipophilic cis‐bis‐carboxylato‐trans‐R, R‐1, 2‐diaminocyclohexane‐platinum (II) complexes into cis‐bisdichloro‐trans‐R, R‐1, 2‐diaminocyclohexane‐platinum (II) . Cancer Chemother. Pharmacol. , 39 , 17 – 24 ( 1996. ). [DOI] [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES